Skip to content
lifestyle.washingtonguardian.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Blue Earth Therapeutics Limited
Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer
July 9, 2026
First Patients in the UK Receive Doses of Blue Earth Therapeutics’ Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastatic Castrate Resistant Prostate Cancer
January 15, 2026